Raloxifene Hydrochloride
Product Images NDC 68071-2412

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Raloxifene Hydrochloride (NDC 68071-2412). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2412 3)

The text appears to be a product label for Raloxifene Hydrochloride tablets manufactured by NuCare Pharmaceuticals, Inc. It provides the NDC, HFR NOC, and expiration date for the product. It also provides information regarding the quantity, tablets strength, and manufacturer's details. The label also includes a warning to keep the product out of reach of children and to store it at a controlled temperature.*

FDA Label Image

\\client\x$\products\raloxifene Hydrochloride Tabs Anda 078193\submissions\2016-03-18 Cbe-0 (AJK\Working\INSERT\Image File\raloxifene-structure01.jpg)

FDA Label Image

\\client\x$\products\raloxifene Hydrochloride Tabs Anda 078193\submissions\2016-03-18 Cbe-0 (AJK\Working\INSERT\Image File\raloxifene-figure01.JPG)

Total hip bone density changes from baseline in subjects who received a placebo and raloxifene hydrochloride for a period of 24 months were analyzed in Study A and EU. The same analysis was done for subjects who received a placebo, raloxifene hydrochloride, and adjusted estrogen (0.625 mg/day) in Study INT, which only included hysterectomized women. The graphs show the percentage change in bone density over time for each group.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.